Amyris (AMRSQ) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 03, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-34885
Entity Registrant Name	AMYRIS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	55-0856151
Entity Address, Address Line One	5885 Hollis Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	450-0761
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	AMRS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		319,714,436
Entity Central Index Key	0001365916
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 287,886	$ 483,462
Restricted cash	174	199
Accounts receivable, net of allowance of $965 and $945, respectively	37,400	37,074
Accounts receivable - related party, net of allowance of $0 and $0, respectively	7,279	5,667
Contract assets	3,883	4,227
Contract assets - related party	8,816	0
Inventories	82,296	75,070
Prepaid expenses and other current assets	43,202	33,513
Total current assets	470,936	639,212
Property, plant and equipment, net	125,264	72,835
Restricted cash, noncurrent	4,651	4,651
Recoverable taxes from Brazilian government entities	22,572	16,740
Right-of-use assets under financing leases, net	457	7,342
Right-of-use assets under operating leases, net	58,937	32,428
Goodwill	136,005	131,259
Intangible assets, net	56,094	39,265
Other assets	23,534	10,566
Total assets	898,450	954,298
Current liabilities:
Accounts payable	88,292	79,666
Accrued and other current liabilities	80,554	71,457
Financing lease liabilities	12	140
Operating lease liabilities	8,120	7,689
Contract liabilities	1,554	2,530
Debt, current portion	1,055	896
Related party debt, current portion (includes instrument measured at fair value of $86,630 and $107,427, respectively)	86,630	107,427
Total current liabilities	266,217	269,805
Long-term debt, net of current portion	672,005	309,061
Financing lease liabilities, net of current portion	58	61
Operating lease liabilities, net of current portion	37,059	19,829
Derivative liabilities	5,247	7,062
Acquisition-related contingent consideration (Note 3 and Note 7)	40,251	64,762
Other noncurrent liabilities	3,490	4,510
Total liabilities	1,024,327	675,090
Commitments and contingencies
Mezzanine equity:
Contingently redeemable common stock	5,000	5,000
Contingently redeemable noncontrolling interest	31,437	28,520
Stockholders’ (deficit) equity:
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2022 and December 31, 2021; zero shares issued and outstanding as of March 31, 2022 and December 31, 2021	0	0
Common stock - $0.0001 par value, 450,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 317,975,269 and 308,899,906 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	32	31
Additional paid-in capital	2,337,634	2,656,838
Accumulated other comprehensive loss	(37,483)	(52,769)
Accumulated deficit	(2,458,973)	(2,357,661)
Total Amyris, Inc. stockholders’ (deficit) equity	(158,790)	246,439
Noncontrolling interest	(3,524)	(751)
Total stockholders' (deficit) equity	(162,314)	245,688
Total liabilities, mezzanine equity and stockholders' (deficit) equity	$ 898,450	$ 954,298

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 965	$ 945
Accounts receivable, allowance, related parties	0	0
Related party debt, net, fair value	$ 86,630	$ 107,427
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	450,000,000	450,000,000
Common stock, shares issued (in shares)	317,975,269	317,975,269
Common stock, shares outstanding (in shares)	308,899,906	308,899,906

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Revenue	$ 57,709	$ 176,859
Cost and operating expenses:
Cost of products sold	48,995	22,659
Research and development	26,358	23,332
Sales, general and administrative	106,916	37,922
Total cost and operating expenses	182,269	83,913
(Loss) income from operations	(124,560)	92,946
Other income (expense):
Interest expense	(5,263)	(5,813)
Gain (loss) from change in fair value of derivative instruments	1,815	(22,745)
Gain (loss) from change in fair value of debt	20,796	(326,785)
Loss upon extinguishment of debt	0	(27,313)
Other expense, net	(3,052)	(678)
Total other income (expense), net	14,296	(383,334)
Loss before income taxes and loss from investment in affiliate	(110,264)	(290,388)
Benefit from (provision for) income taxes	820	(55)
(Loss) income from investment in affiliate	(789)	392
Net loss	(110,233)	(290,051)
Loss (income) attributable to noncontrolling interest	2,928	(1,200)
Net loss attributable to Amyris, Inc.	(107,305)	(291,251)
Less: loss allocated to participating securities	0	2,099
Net loss attributable to Amyris, Inc. common stockholders, basic	$ (107,305)	$ (289,152)
Earnings Per Share, Basic [Abstract]
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.34)	$ (1.08)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)	312,896,452	267,733,555
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.37)	$ (1.08)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)	323,711,682	267,733,555
Renewable Products
Revenue:
Revenue	$ 43,465	$ 28,179
Licenses and Royalties
Revenue:
Revenue	9,313	143,800
Collaborations, Grants and Other
Revenue:
Revenue	$ 4,931	$ 4,880

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues, related party	$ 15,228	$ 147,274
Renewable Products
Revenues, related party	4,412	1,662
Licenses and Royalties
Revenues, related party	8,816	143,612
Collaborations, Grants and Other
Revenues, related party	$ 2,000	$ 2,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Comprehensive loss:
Net loss	$ (110,233)	$ (290,051)
Foreign currency translation adjustment	15,286	(2,038)
Total comprehensive loss	(94,947)	(292,089)
Loss (income) attributable to noncontrolling interest	2,928	(1,200)
Comprehensive loss attributable to Amyris, Inc.	$ (92,019)	$ (293,289)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Deficit) and Mezzanine Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Preferred Stock	Common Stock	Additional Paid-in Capital	Additional Paid-in CapitalCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2020			8,280	244,951,446
Beginning balance at Dec. 31, 2020	$ (172,045)		$ 0	$ 24	$ 1,957,224		$ (47,375)	$ (2,086,692)		$ 4,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)				496,341
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	(2)				(2)
Issuance of common stock and warrants upon conversion of debt principal (in shares)				5,827,164
Issuance of common stock and warrants upon conversion of debt principal	110,575			$ 1	110,574
Issuance of common stock upon exercise of stock options (in shares)				377,542
Issuance of common stock upon exercise of stock options	1,920				1,920
Issuance of common stock upon exercise of warrants (in shares)				15,557,480
Issuance of common stock upon exercise of warrants	32,219			$ 2	32,217
Issuance of common stock upon exercise of warrants - related party (in shares)				6,056,944
Stock-based compensation	4,281				4,281
Foreign currency translation adjustment	(2,038)						(2,038)
Net loss attributable to Amyris, Inc.	(290,051)							(291,251)		1,200
Ending balance (in shares) at Mar. 31, 2021			8,280	273,266,917
Ending balance at Mar. 31, 2021	(315,141)		$ 0	$ 27	2,106,214		(49,413)	(2,377,943)		5,974
Beginning balance, contingently redeemable common stock at Dec. 31, 2020	5,000
Ending balance, contingently redeemable common stock at Mar. 31, 2021	5,000
Beginning balance (in shares) at Dec. 31, 2020			8,280	244,951,446
Beginning balance at Dec. 31, 2020	$ (172,045)		$ 0	$ 24	1,957,224		(47,375)	(2,086,692)		4,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting standards update [extensible list]	Accounting Standards Update 2020-06 [Member]
Ending balance (in shares) at Dec. 31, 2021				308,899,906
Ending balance at Dec. 31, 2021	$ 245,688	$ (361,981)		$ 31	2,656,838	$ (367,974)	(52,769)	(2,357,661)	$ 5,993	(751)
Beginning balance, contingently redeemable common stock at Dec. 31, 2020	5,000
Ending balance, contingently redeemable common stock at Dec. 31, 2021	5,000
Ending balance, contingently redeemable noncontrolling interest at Dec. 31, 2021	28,520
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Acquisitions	155									155
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares)				528,704
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock	(3)				(3)
Issuance of common stock as purchase consideration in business combinations (in shares)				7,121,806
Issuance of common stock as purchase consideration in business combinations	$ 33,094			$ 1	33,093
Issuance of common stock upon exercise of stock options (in shares)	34,541			33,250
Issuance of common stock upon exercise of stock options	$ 98				98
Issuance of common stock upon exercise of warrants (in shares)				1,391,603
Issuance of common stock upon exercise of warrants	3,994				3,994
Stock-based compensation	11,588				11,588
Foreign currency translation adjustment	15,286						15,286
Net loss attributable to Amyris, Inc.	(110,233)							(107,305)		(2,928)
Ending balance (in shares) at Mar. 31, 2022				317,975,269
Ending balance at Mar. 31, 2022	(162,314)			$ 32	$ 2,337,634		$ (37,483)	$ (2,458,973)		$ (3,524)
Mezzanine Equity
Contingently redeemable noncontrolling interest, acquisitions	2,917
Ending balance, contingently redeemable common stock at Mar. 31, 2022	5,000
Ending balance, contingently redeemable noncontrolling interest at Mar. 31, 2022	$ 31,437

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Stockholders' Equity (Deficit) and Mezzanine Equity (Parentheticals)	3 Months Ended
	Mar. 31, 2021shares
2026 convertible senior notes | Convertible notes
Shares to be returned per agreement (in shares)	2,600,000

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (110,233)	$ (290,051)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of debt discount	962	713
Amortization of intangible assets	892	0
Amortization of right-of-use assets under operating leases	754	750
Depreciation and amortization	2,400	2,114
(Gain) loss from change in fair value of debt	(20,796)	326,785
(Gain) loss from change in fair value of derivative instruments	(1,815)	22,745
Loss (gain) from investment in affiliate	789	(392)
Loss on foreign currency exchange rates	1,519	408
Loss upon extinguishment of debt	0	27,313
Stock-based compensation	11,588	4,281
Changes in assets and liabilities:
Accounts receivable	(1,554)	17,275
Contract assets	(8,472)	(3,208)
Inventories	(5,001)	(5,686)
Deferred cost of products sold - related party	0	5,129
Prepaid expenses and other assets	(23,881)	(8,207)
Accounts payable	5,007	4,154
Accrued and other liabilities	6,026	4,011
Lease liabilities	(9,658)	(1,185)
Contract liabilities	(969)	1,702
Net cash provided by (used in) operating activities	(152,442)	108,651
Investing activities
Purchases of property, plant and equipment	(33,751)	(2,493)
Acquisitions, net of cash acquired	(13,535)	0
Net cash used in investing activities	(47,286)	(2,493)
Financing activities
Issuance costs incurred in connection with debt modification	0	(2,500)
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units	(3)	(2)
Principal payments on debt	0	(23,196)
Principal payments on financing leases	(131)	(912)
Proceeds from exercises of common stock options	98	1,920
Proceeds from exercises of warrants	3,994	32,219
Net cash provided by financing activities	3,958	7,529
Effect of exchange rate changes on cash, cash equivalents and restricted cash	169	(44)
Net increase in cash, cash equivalents and restricted cash	(195,601)	113,643
Cash, cash equivalents and restricted cash at beginning of period	488,312	31,422
Cash, cash equivalents and restricted cash at end of the period	292,711	145,065
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	287,886	143,821
Restricted cash, current	174	283
Restricted cash, noncurrent	4,651	961
Total cash, cash equivalents and restricted cash	292,711	145,065
Supplemental disclosures of cash flow information:
Cash paid for interest	52	3,275
Supplemental disclosures of non-cash investing and financing activities:
Acquisition of intangible assets in connection with business combinations	18,417	0
Acquisition of right-of-use assets under operating leases	27,165	0
Common stock and warrants issued in exchange for debt principal and accrued interest reduction	0	110,575
Common stock issued as purchase consideration in business combinations	33,094	0
Derecognition of derivative liabilities to equity upon extinguishment of debt	0	59
Goodwill recorded in connection with business combinations	7,666	0
Noncontrolling interest recorded in connection with business combinations	3,072	0
Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period	$ 4,995	$ 1,121

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Amyris, Inc. and subsidiaries (collectively, Amyris or the Company) is a biotechnology company delivering sustainable solutions for people and the planet. The Company creates, manufactures and commercializes consumer products and ingredients. Currently, the largest driver of the Company's revenue is derived from marketing and selling Clean Beauty, Personal Care and Health & Wellness consumer products through direct-to-consumer ecommerce platforms and a growing network of retail partners. The Company also sells sustainable ingredients to sector leaders that serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The Company's ingredients and consumer products are powered by the Company's fermentation-based Lab-to-Market TM technology platform, which leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the Company to rapidly bring new innovation to market. The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the 2021 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2021 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. Significant Accounting Policies Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2021 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the three months ended March 31, 2022. Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed. Accounting Update Recently Adopted In the three months ended March 31, 2022, the Company adopted this accounting update: Convertible Debt, and Derivatives and Hedging . In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 became effective for the Company in the first quarter of 2022. Adoption of this standard on January 1, 2022 in connection with the 2026 Convertible Senior Notes (see Note 4, "Debt"), decreased additional paid-in capital by $368.0 million, increased debt by the same amount and decreased accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption. Accounting Standards or Updates Not Yet Adopted Credit Losses . In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. Because the Company met the SEC definition of a smaller reporting company when ASU 2016-13 was issued, this new accounting standard will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures. Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers . This standard will be effective for the Company in the first quarter of 2023 and will be applied prospectively to business combinations occurring on or after the effective date of the standard. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the guidance and the impact on its consolidated financial statements and related disclosures.

Balance Sheet Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Details	Balance Sheet Details Allowance for Doubtful Accounts (In thousands) Balance at Beginning of Period Provisions Write-offs, Net Balance at End of Period Three months ended March 31, 2022 $ 945 $ 20 $ — $ 965 Three months ended March 31, 2021 $ 137 $ 17 $ — $ 154 Inventories (In thousands) March 31, 2022 December 31, 2021 Raw materials $ 27,764 $ 25,733 Work-in-process 6,949 6,941 Finished goods 47,583 42,396 Inventories $ 82,296 $ 75,070 Prepaid Expenses and Other Current Assets (In thousands) March 31, 2022 December 31, 2021 Prepayments, advances and deposits $ 34,444 $ 25,140 Non-inventory production supplies 3,762 3,956 Recoverable taxes from Brazilian government entities 1,298 1,188 Other 3,698 3,229 Total prepaid expenses and other current assets $ 43,202 $ 33,513 Property, Plant and Equipment, Net (In thousands) March 31, 2022 December 31, 2021 Manufacturing facilities and equipment $ 69,126 $ 51,855 Leasehold improvements 48,483 45,780 Computers and software 9,481 9,174 Furniture and office equipment, vehicles and land 3,789 3,688 Construction in progress 89,656 48,032 220,535 158,529 Less: accumulated depreciation and amortization (95,271) (85,694) Property, plant and equipment, net $ 125,264 $ 72,835 During the three months ended March 31, 2022 and 2021, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows: Three Months Ended March 31, (In thousands) 2022 2021 Depreciation and amortization expense $ 2,400 $ 2,114 Goodwill The changes in the carrying amount of goodwill were as follows: (In thousands) March 31, 2022 Balance at beginning of year $ 131,259 Acquisitions 7,666 Effect of currency translation adjustment (2,920) Ending balance $ 136,005 Additions to goodwill during the three months ended March 31, 2022 related to acquisitions completed during the period. See Note 7, "Acquisitions". Intangible Assets, Net During the three months ended March 31, 2022, the Company recorded $18.4 million of intangible assets which related to customer relationships, trademarks and trade names, branded products, and software as a result of the acquisitions completed during the period. See Note 7, "Acquisitions". The following table summarizes the components of intangible assets (in thousands, except estimated useful life): March 31, 2022 December 31, 2021 Amounts in thousands Estimated Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net Trademarks and trade names, and branded products 10 $ 25,704 $ (953) $ 24,751 $ 11,484 $ (496) $ 10,988 Customer relationships 5 - 16 8,638 (474) 8,164 8,197 (267) 7,930 Developed technology and software applications 5 - 12 23,003 (400) 22,603 19,962 (200) 19,762 Patents 17 600 (24) 576 600 (15) 585 Total intangible assets $ 57,945 $ (1,851) $ 56,094 $ 40,243 $ (978) $ 39,265 Amortization expense for intangible assets was $0.9 million for the three months ended March 31, 2022 and is included in general and administrative expenses. Total future amortization of intangible assets as of March 31, 2022 is as follows (in thousands): Amounts in thousands 2022 (remainder) $ 3,188 2023 5,875 2024 7,027 2025 7,177 2026 6,933 Thereafter 25,894 Total future amortization $ 56,094 Leases Operating Leases The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 18 years, and often include one or more options to renew. These renewal terms can extend the lease term for an additional 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $58.9 million and $32.4 million of right-of-use assets as of March 31, 2022 and December 31, 2021, respectively. Operating lease liabilities were $45.2 million and $27.5 million as of March 31, 2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, respectively, the Company recorded $3.7 million and $1.8 million of operating lease amortization that was charged to expense, of which $0.3 million and $0.2 million was recorded to cost of products sold. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component. Information related to the Company's right-of-use assets and related lease liabilities were as follows: Three Months Ended March 31, 2022 2021 Cash paid for operating lease liabilities, in thousands $3,045 $1,185 Right-of-use assets obtained in exchange for new operating lease obligations, in thousands $18,759 $— Weighted-average remaining lease term 8.7 2.7 Weighted-average discount rate 19.0% 18.0% Financing Leases The Company has financing leases primarily for laboratory equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $1.3 million and $6.8 million as of March 31, 2022 and December 31, 2021, respectively. Maturities of Financing and Operating Leases Maturities of lease liabilities as of March 31, 2022 were as follows: Years ending December 31: (In thousands) Financing Operating Total Leases 2022 (Remaining Nine Months) $ 16 $ 10,038 $ 10,054 2023 22 11,638 11,660 2024 21 9,145 9,166 2025 21 8,964 8,985 2026 16 8,953 8,969 Thereafter — 51,221 51,221 Total lease payments 96 99,959 100,055 Less: amount representing interest (26) (54,780) (54,806) Total lease liability $ 70 $ 45,179 $ 45,249 Current lease liability $ 12 $ 8,120 $ 8,132 Noncurrent lease liability 58 37,059 37,117 Total lease liability $ 70 $ 45,179 $ 45,249 Other Assets (In thousands) March 31, 2022 December 31, 2021 Investment in non-trade receivable (1) $ 10,049 $ — Equity-method investments in affiliates 9,654 9,443 Deposits 447 129 Other 3,384 994 Total other assets $ 23,534 $ 10,566 ______________ (1) In March 2022, the Company loaned a privately held company $10 million in exchange for a senior secured convertible promissory note (the Note) which matures in March 2025, unless earlier redeemed or converted into equity of the privately held company. The Note bears interest at 8% per annum and is convertible, at the Company's option, into equity of the privately held company upon maturity of the Note or in the event of an initial public offering, equity financing, or corporate transaction (such as a sale or merger), in each case, at a conversion price that is dependent on a variety of factors. In addition, the Note is redeemable prior to maturity, at the issuer's option, in the event of one or more equity or debt financings, one or more asset sales, or an initial public offering, in each case equal to or greater than $50 million in the aggregate. The Company concluded that the arrangement qualifies for accounting as a loan as required by ASC 310-10. The Company will periodically evaluate the collectibility of the loan, and an allowance for credit losses will be recorded when the Company concludes that all or a portion of the loan balance is no longer collectible. Accrued and Other Current Liabilities (In thousands) March 31, 2022 December 31, 2021 Business acquisitions contingent consideration payable (1) $ 24,872 $ — Accrued interest 12,957 9,572 Payroll and related expenses 11,178 9,151 Liability in connection with acquisition of equity-method investment 9,309 8,735 Beauty Labs deferred consideration payable (2) 5,369 30,000 Asset retirement obligation (3) 4,145 3,336 Professional services 3,057 2,447 Contract termination fees 1,407 1,345 Tax-related liabilities 1,233 988 License fee payable 1,050 1,050 Other 5,977 4,833 Total accrued and other current liabilities $ 80,554 $ 71,457 ______________ (1) Business acquisitions contingent consideration payable is the current portion of total acquisition-related contingent consideration. (2) Approximately $23.7 million of the $30.0 million of Beauty Labs deferred consideration was settled with Amyris common stock in March 2022. (3) The asset retirement obligation represents liabilities incurred but not yet discharged in connection with the Company's 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) March 31, 2022 December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities Foris Convertible Note (LSA Amendment) $ — $ — $ 86,630 $ 86,630 $ — $ — $ 107,427 $ 107,427 Freestanding derivative instruments issued in connection with debt and equity instruments — — 5,247 5,247 — — 7,062 7,062 Total liabilities measured and recorded at fair value $ — $ — $ 91,877 $ 91,877 $ — $ — $ 114,489 $ 114,489 The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of March 31, 2022 and December 31, 2021. Also, there were no transfers between the levels during the three months ended March 31, 2022 or the year ended December 31, 2021. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments". Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt". Fair Value of Debt — Foris Convertible Note At March 31, 2022, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $86.6 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $4.36 stock price, (ii) 21% discount yield, (iii) 0.52% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. For the three months ended March 31, 2022, the Company recorded a gain of $20.8 million related to change in fair value of the Foris Convertible Note. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price. Binomial Lattice Model A binomial lattice model was used to determine whether the Foris Convertible Note would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Foris Convertible Note using the "with-and-without method", where the fair value of the Foris Convertible Note including the embedded features is defined as the "with," and the fair value of the Foris Convertible Note excluding the embedded features is defined as the "without." This method estimates the fair value of the Foris Convertible Note by considering the incremental value of the Foris Convertible Note with the embedded features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Foris Convertible Note and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period. Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3): (In thousands) Derivative Liability Balance at December 31, 2021 $ 7,062 Change in fair value of derivative instruments (1,815) Derecognition on settlement or extinguishment — Balance at March 31, 2022 $ 5,247 Valuation Methodology and Approach to Measuring the Derivative Liabilities The Company's outstanding derivative liabilities at March 31, 2022 and December 31, 2021 represent the fair value of a freestanding equity instrument. See Note 6, "Stockholders' Deficit" for further information regarding the host instrument. There is no current observable market for this type of derivative and, as such, the Company determined the fair value of the freestanding instrument using the Black-Scholes-Merton option pricing model, which is discussed in more detail below. The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants as of March 31, 2022 and December 31, 2021. Input assumptions for the freestanding instrument are as follows: Range for the Period Input assumptions for liability classified warrants: March 31, 2022 December 31, 2021 Fair value of common stock on issue date $4.36 $5.41 Exercise price of warrants $2.87 $2.87 Expected volatility 106% 107% Risk-free interest rate 2.28% 0.07% – 0.28% Expected term in years 2 2 Dividend yield 0.0 % 0.0 % Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields, term to maturity/conversion or stock price volatility increases the value of the derivative liability. Acquisition related contingent consideration The fair value of acquisition related contingent consideration (Earnout Payments) was determined using a Monte Carlo simulation to estimate the probability of the acquired business units achieving the relevant financial and operational milestones. The model results reflect the time value of money, non-performance risk within the required time frame and the risk due to uncertainty in the estimated cash flows. Key inputs to the Monte Carlo simulation for the MenoLabs acquisition were: Revenue Risk Adjustment of 6.2% and Annual Revenue Volatility of 35%. A significant decrease or increase in an acquired business unit’s financial performance and the timing of such changes could materially decrease or increase the fair value of contingent consideration period over period. Contingent consideration is recorded in other liabilities in the accompanying consolidated balance sheets. The fair value of contingent consideration is classified as Level 3. The changes in fair value are as follows: (In thousands) March 31, 2022 Beginning balance January 1, 2022 $ 64,762 MenoLabs acquisition 440 Adjustment (79) Change in fair value of contingent consideration — Ending balance March 31, 2022 $ 65,123 Any change in the fair value of the contingent consideration liability is recognized in general and administrative expense and reflects the changes in the business unit’s expected performance over the remaining earnout period and the Company’s estimate of the likelihood of achieving the applicable operational milestones (see Note 7, “Acquisitions”). Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at March 31, 2022 and at December 31, 2021, excluding the debt instruments recorded at fair value, was $673.1 million and $310.0 million, respectively. The fair value of such debt at March 31, 2022 and at December 31, 2021 was $249.3 million and $328.0 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments.

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	Debt Net carrying amounts of debt are as follows: March 31, 2022 December 31, 2021 (In thousands) Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Convertible notes 2026 convertible senior notes $ 690,000 $ (17,995) $ — $ 672,005 $ 690,000 $ (380,939) $ — $ 309,061 Related party convertible notes Foris convertible note (due July 2022) 50,041 — 36,589 86,630 50,041 — 57,386 107,427 Loans payable and credit facilities Other loans payable (revolving) 1,055 — — 1,055 896 — — 896 Total debt $ 741,096 $ (17,995) $ 36,589 759,690 $ 740,937 $ (380,939) $ 57,386 417,384 Less: current portion (87,686) (108,323) Long-term debt, net of current portion $ 672,004 $ 309,061 Interest expense was as follows: Three Months Ended March 31, (In thousands) 2022 2021 Contractual interest expense in connection with debt $ 3,415 $ 3,553 Debt discount accretion 962 713 Interest expense in connection with debt 4,377 4,266 Financing lease interest expense 3 165 Discount accretion on liability in connection with acquisition of equity-method investment and with partnership liability, and other 883 1,382 Total interest expense $ 5,263 $ 5,813 Adoption of ASU 2020-06 ASU 2020-06 became effective for the Company in the first quarter of 2022. The January 1, 2022 adoption of this standard, in connection with the 2026 Convertible Senior Notes, decreased additional paid-in capital by $368.0 million, increased debt by the same amount, and decreased the accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption. Future Minimum Payments Future minimum payments under the Company's debt agreements as of March 31, 2022 are as follows: (In thousands) Convertible Notes Related Party Convertible Notes Loans Total 2022 (Remaining Nine Months) $ 10,321 $ 59,578 $ 157 $ 70,056 2023 10,350 — 1,129 11,479 2024 10,350 — — 10,350 2025 10,350 — — 10,350 2026 700,379 — — 700,379 Thereafter — — — — Total future minimum payments 741,750 59,578 1,286 802,614 Less: amount representing interest (51,750) (9,537) (231) (61,518) Present value of minimum debt payments 690,000 50,041 1,055 741,096 Less: current portion of debt principal — (50,041) — (50,041) Noncurrent portion of debt principal $ 690,000 $ — $ 1,055 $ 691,055

Mezzanine Equity

Mezzanine Equity	3 Months Ended
	Mar. 31, 2022
Temporary Equity Disclosure [Abstract]
Mezzanine Equity	Mezzanine Equity Gates Foundation Contingently redeemable common stock as of March 31, 2022 and December 31, 2021 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill & Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults on its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%. The Company concluded a redemption event was not probable to occur. As of March 31, 2022, the Company's remaining research and development obligation under this arrangement was $0.2 million. Ingredion Contingently Redeemable Noncontrolling Interest in Subsidiary On June 1, 2021, the Company entered into a Membership Interest Purchase Agreement (MIPA) with Ingredion Corporation (Ingredion) to purchase 31% of the member units in RealSweet LLC (RealSweet), a 100% owned Amyris, Inc. subsidiary. Total consideration was $28.5 million in the form of a $10 million cash payment, the exchange of a $4 million payable previously due to Ingredion and $14.5 million of manufacturing intellectual property rights. The terms of the MIPA provide both parties with put/call rights under certain circumstances, including the occurrence of either or both of the following: (i) a change in ownership of fifty percent (50%) or more of the voting shares of such Member; or (ii) a change in the right to appoint or remove a majority of the board of directors of such Member. The Company concluded this change in control provision was not solely within its control and Ingredion’s contingently redeemable noncontrolling interest should be reflected outside of permanent equity in accordance with SEC’s Accounting Series Release 268, Presentation in Financial Statements of Redeemable Preferred Stocks (ASR 268). The redemption price of this common-share noncontrolling interest is considered to be at fair value on the redemption date. Ingredion’s noncontrolling interest is not currently redeemable and the Company concluded a contingent redemption event is not probable to occur. The primary redemption contingency relates to a decrease in Ingredion’s ownership percentage below 8.4%, which is not likely to occur given that capital transactions require the unanimous consent of each member. Consequently, the noncontrolling interest will not be subsequently remeasured to its redemption amount until such contingency event and the related redemption are probable to occur; however, the Company will continue to reflect the attribution of any losses and distribution of dividends to the noncontrolling interest each quarter in accordance with ASC 810-10. At the transaction date, the Company recorded the $28.5 million noncontrolling interest in RealSweet as Mezzanine equity - contingently redeemable noncontrolling interest, which represented the value of Ingredion’s 31% ownership interest in the net assets of the RealSweet subsidiary. Under the terms of the MIPA, Amyris, Inc., is funding the construction costs of the project, which are estimated to be approximately $115 million. As of March 31, 2022, the Company has funded approximately $68 million towards the project and has $38 million of contractual purchase commitments for construction related costs. EcoFabulous Contingently Redeemable Noncontrolling Interest in Subsidiary On January 26, 2022, the Company and certain of its subsidiaries entered into an Agreement and Plan of Merger for the acquisition of 70% of No Planet B LLC (d/b/a EcoFabulous), a privately held company. In connection with the merger, the name of No Planet B LLC has been changed to EcoFab, LLC (EcoFab). No Planet B Investments, LLC holds 30% of the outstanding units of membership interests in EcoFab as of the effective time of the merger (the Minority Member). See Note 7, "Acquisitions". Concurrently, the Company and No Planet B Investments, LLC entered into the EcoFab, LLC Agreement, the terms of which provide the Minority Member a right to require EcoFab to repurchase its 30% noncontrolling interest after (i) EcoFab achieving Net Revenues in excess of $100 million on an annualized basis or, if earlier, (ii) December 31, 2026. The Company concluded this provision was not solely within its control and EcoFab’s contingently redeemable noncontrolling interest should be reflected outside of permanent equity in accordance with SEC’s Accounting Series Release 268, Presentation in Financial Statements of Redeemable Preferred Stocks (ASR 268) and ASC 480-10-S99, “Distinguishing Liabilities from Equity” (ASC 480).

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Deficit	Stockholders' (Deficit) Equity Warrants and Rights Activity Summary In connection with various debt and equity transactions (see Note 4, “Debt” above, and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2021 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at March 31, 2022: Transaction Year Issued Expiration Date Number Outstanding as of December 31, 2021 Exercises Expired Exercise Price per Share of Warrants Exercised Number Outstanding as of March 31, 2022 Exercise Price per Share as of March 31, 2022 Blackwell / Silverback warrants 2020 July 10, 2022 1,000,000 — — 1,000,000 $ 3.25 January 2020 warrant exercise right shares 2020 January 31, 2022 431,378 (431,378) — $ 2.87 — $ — May 2019 6.50% Note Exchange warrants 2019 January 31, 2022 960,225 (960,225) — $ 2.87 — $ — May 2017 cash warrants 2017 July 10, 2022 1,492,652 — 1,492,652 $ 2.87 May 2017 dilution warrants 2017 July 10, 2022 56,910 — — 56,910 $ — July 2015 related party debt exchange 2015 July 29, 2025 58,690 — — 58,690 $ 0.15 3,999,855 (1,391,603) — $ 2.87 2,608,252 Warrant Exercises During the three months ended March 31, 2022, warrant-holders exercised warrants to purchase 1,391,603 shares of the Company’s common stock at a weighted-average exercise price of $2.87 per share, for proceeds to the Company of $4.0 million.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions The purchase accounting for the net assets acquired, including goodwill, and the fair value of the contingent consideration and noncontrolling interest for the following acquisitions is preliminarily recorded based on available information and incorporates management's best estimates. The purchase accounting for taxes remains preliminary pending receipt of certain information required to finalize the determination of fair value. The net assets acquired in the transaction are generally recorded at their estimated acquisition-date fair values, while transaction costs associated with the acquisition are expensed as incurred. These transactions were accounted for by the acquisition method, and accordingly, the results of operations were included in the Company’s consolidated financial statements from their respective acquisition dates. Pro forma financial information is not presented as amounts are not material to the Company’s consolidated financial statements. EcoFab LLC. On January 26, 2022, the Company and certain of its subsidiaries entered into an Agreement and Plan of Merger for the acquisition of 70% of No Planet B LLC (d/b/a EcoFabulous), a privately held company. EcoFabulous is focused on delivering high performance, makeup artist-quality clean beauty products in ecofriendly packaging, and priced for Gen Z consumers. In connection with the merger, the name of No Planet B LLC has been changed to EcoFab, LLC (EcoFab). No Planet B Investments, LLC holds 30% of the outstanding units of membership interests in EcoFab as of the effective time of the merger, which is accounted for as Mezzanine equity - contingently redeemable noncontrolling interest. See Note 5, "Mezzanine Equity". The purchase consideration for the acquisition of EcoFab consisted of $1.7 million in cash and 1,292,776 shares of Amyris stock with a fair value of $5.5 million. The noncontrolling interest had a fair value of $3.1 million as of the acquisition date. The following table summarizes the purchase price allocation: (In thousands) Trademarks, trade names and other intellectual property $ 8,705 Customer relationships 512 Goodwill 1,023 Less: noncontrolling interest $ (3,072) Total consideration $ 7,168 Goodwill associated with this acquisition is expected to be deductible for tax purposes. The Company has determined that (i) EcoFab is a variable-interest entity (VIE) due to insufficient equity at risk, (ii) the Company is the primary beneficiary of EcoFab due to its power to direct the activities that most significantly affect EcoFab’s economic performance, and (iii) the Company has the ability to exert significant influence over EcoFab through its 70% equity ownership. As a result, the Company accounts for its investment in EcoFab on a consolidation basis in accordance with ASC 810, Consolidation. MenoLabs, LLC. On March 9, 2022, Amyris and Amyris Clean Beauty, Inc., a wholly owned subsidiary of Amyris, entered into an Asset Purchase Agreement with MenoLabs, LLC, (MenoLabs), an Arizona limited liability company, to purchase substantially all of the assets and assume the liabilities of MenoLabs. The transaction closed on March 10, 2022 (the Closing Date). MenoLabs was founded to fundamentally change how menopause is addressed by offering research-backed all-natural treatments of menopause symptoms. Prior to the Closing Date, Amyris and MenoLabs entered into that certain Loan Agreement and Promissory Note in January 2022, pursuant to which Amyris loaned to MenoLabs the aggregate principal amount of $0.5 million. In connection with the acquisition of MenoLabs, Amyris has assumed the Bridge Loan. The acquisition of MenoLabs will serve as a catalyst to accelerate growth and establish a leadership position in the fast-growing menopause market. MenoLabs was acquired for total purchase consideration of $16.2 million, consisting of $11.3 million in cash, the Bridge Loan of $0.5 million, 852,234 shares of Amyris stock with a fair value of $3.9 million, and contingent consideration with a fair value of $0.4 million. The contingent consideration consists of two potential payments of up to $10 million each during the twelve (12) month period beginning on the first day of the first calendar month commencing after the Closing Date and the fourth quarter of 2024 respectively if both MenoLabs’s product revenues and profit margin meet the targets set forth for such period in the Asset Purchase Agreement (the Earnout Payments). The Earnout Payments will be in the form of cash or in an aggregate number of shares of Amyris Stock equal to the earnout achieved divided by the stock price on achievement date, at Amyris’s sole discretion. The $0.4 million fair value of the Earnout Payments is recorded as other liabilities in the accompanying condensed consolidated balance sheets. Allocation of the contingent consideration payments between short-term and long-term liabilities on the accompanying consolidated balance sheets is based on management’s best estimates of when the relevant milestone will be achieved. The following table summarizes the purchase price allocation: (In thousands) Net tangible assets $ 311 Branded products 5,600 Application (App) 3,600 Goodwill 6,642 Total consideration $ 16,153 Goodwill associated with this acquisition is expected to be deductible for tax purposes.

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses. The following table presents the calculation of basic and diluted loss per share: Three Months Ended March 31, (In thousands, except shares and per share amounts) 2022 2021 Numerator: Net loss attributable to Amyris, Inc. $ (107,305) $ (291,251) Less: loss allocated to participating securities — 2,099 Net loss attributable to Amyris, Inc. common stockholders, basic $ (107,305) $ (289,152) Interest on convertible debt 457 — Gain from change in fair value of debt (12,650) — Gain from change in fair value of derivative instruments (1,815) — Net loss attributable to Amyris, Inc. common stockholders, diluted $ (121,313) $ (289,152) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 312,896,452 267,733,555 Net loss per share, basic $ (0.34) $ (1.08) Weighted-average shares of common stock outstanding 312,896,452 267,733,555 Effect of dilutive convertible debt 10,146,017 — Effect of dilutive common stock warrants 669,213 — Weighted-average shares of common stock equivalents used in computing net loss per share of common stock, diluted 323,711,682 267,733,555 Net loss per share, diluted $ (0.37) $ (1.08) For the three months ended March 31, 2022 and 2021, basic income per share differed from diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was dilutive. The following table presents outstanding shares of potentially dilutive securities: Three Months Ended March 31, 2022 2021 Period-end common stock warrants 2,492,652 13,416,235 Convertible promissory notes (1) 86,683,389 19,540,447 Period-end stock options to purchase common stock 3,800,314 6,205,576 Period-end restricted stock units 17,305,337 6,653,640 Contingently issuable common shares 1,718,475 — Period-end preferred stock — 1,943,661 Total potentially dilutive securities excluded from computation of diluted loss per share 112,000,167 47,759,559 ______________ (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and ContingenciesGuarantor Arrangements The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of March 31, 2022 and December 31, 2021. The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM, the Company's international subsidiaries and the Company’s ownership interests in joint ventures. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note. In October 2021, the Company entered into a 10-year manufacturing partnership agreement with Renfield Manufacturing, LLC (Renfield) to provide manufacturing services and third-party logistics processes, including inventory management, warehousing, and fulfillment for certain of the Company’s consumer product lines. The Company also provided a $0.5 million letter of credit and guarantee to the lessor of the Renfield manufacturing facility, which extends through August 2032. If Renfield fails to perform under the facility lease, the Company can terminate the manufacturing agreement. The Company expects that its potential future performance under the guarantee is not probable of occurrence. Accordingly, the Company had no liabilities recorded for the guarantee as of March 31, 2022 and December 31, 2021. Other Matters Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed. On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. In early 2021, the parties attended court-ordered mediation, but as the case did not settle, the parties commenced discovery. On July 30, 2021, plaintiffs filed a motion seeking class certification and the Company filed its opposition on September 24, 2021; after briefing and argument, it was granted in part on December 8, 2021. On December 22, 2021, the Company filed a petition seeking interlocutory review of that order in the U.S. Court of Appeals for the Ninth Circuit, which was fully briefed on January 14, 2022. On February 4, 2022, the parties reached a tentative settlement of the securities class action, which requires the court’s review and approval. On March 24, 2022, the parties submitted the proposed settlement agreement to the Court. If the settlement is approved by the Court, the settlement amount will be covered by the Company’s directors and officers insurance policy. Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021 and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021 and refiled in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. The motion to dismiss was granted without prejudice on June 30, 2021. After obtaining an extension, Bonner amended his complaint on February 22, 2022. On March 24, 2022, the Company filed a motion seeking full dismissal with prejudice of claims alleged in Bonner’s amended complaint. An oral argument on the Company's motion to dismiss is scheduled for June 9, 2022. The Company believes the amended complaint lacks merit, and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result from these matters. On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended (Cannabinoid Agreement). The Company filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The Court denied the Company's motions on July 26, 2021, and the Company appealed the Court's ruling regarding its motion to compel arbitration on July 27, 2021 and filed its appeal to the U.S. Court of Appeals for the Second Circuit on November 4, 2021. While the appellate briefing process was completed on January 19, 2022, the Court has not yet scheduled oral argument. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom. The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s expectations, the Company’s condensed consolidated financial statements for the relevant reporting period could be materially adversely affected.

Revenue Recognition and Contrac

Revenue Recognition and Contract Assets and Liabilities	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition and Contract Assets and Liabilities	Revenue Recognition, and Contract Assets and Liabilities Disaggregation of Revenue The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended March 31, (In thousands) 2022 2021 Renewable Products Licenses and Royalties Collaborations, Grants and Other Total Renewable Products Licenses and Royalties Collaborations, Grants and Other Total North America $ 32,956 $ 433 $ 1,476 $ 34,865 $ 20,090 $ — $ 250 $ 20,340 Europe 7,289 8,880 3,263 19,432 2,972 143,800 2,346 149,118 Asia 1,488 — 192 1,680 4,405 — 2,284 6,689 South America 1,019 — — 1,019 313 — — 313 Other 713 — — 713 399 — — 399 $ 43,465 $ 9,313 $ 4,931 $ 57,709 $ 28,179 $ 143,800 $ 4,880 $ 176,859 The following table presents revenue by major product and service, as well as by management classification: Three Months Ended March 31, (In thousands) 2022 2021 Renewable Products Licenses and Royalties Grants, Collaborations and Other Total Renewable Products Licenses and Royalties Grants, Collaborations and Other Total Consumer $ 32,642 $ 433 $ 1,476 $ 34,551 $ 15,653 $ — $ — $ 15,653 Technology access 10,823 8,880 3,455 23,158 12,526 143,800 4,880 161,206 $ 43,465 $ 9,313 $ 4,931 $ 57,709 $ 28,179 $ 143,800 $ 4,880 $ 176,859 Significant Revenue Agreements and Customers In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2021 Form 10-K), the Company recognized the following revenue: Three Months Ended March 31, (In thousands) 2022 2021 Renewable Products Licenses and Royalties Collaborations, Grants and Other Total Renewable Products Licenses and Royalties Collaborations, Grants and Other Total DSM - related party $ 4,412 $ 8,816 $ 2,000 $ 15,228 $ 1,662 $ 143,612 $ 2,000 $ 147,274 Sephora 7,633 — — 7,633 4,441 — — 4,441 PureCircle 1,551 — — 1,551 — — — — Subtotal revenue from significant revenue agreements 13,596 8,816 2,000 24,412 6,103 143,612 2,000 151,715 Revenue from all other customers 29,869 497 2,931 33,297 22,076 188 2,880 25,144 Total revenue from all customers $ 43,465 $ 9,313 $ 4,931 $ 57,709 $ 28,179 $ 143,800 $ 4,880 $ 176,859 DSM Ingredients Collaboration Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with payments of $2.0 million quarterly from January 1, 2022 to June 30, 2022 for services focused on achieving certain fermentation yield and cost targets related to certain molecules. During the three months ended March 31, 2022, the Company recognized $2.0 million of collaboration revenue in connection with the agreement. DSM License Agreement and Contract Assignment In March 2021 the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property of the Company and assigned the Company’s rights and obligations under certain F&F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain commercial milestones are achieved in each of the calendar years 2022 through 2024. The Company determined the licenses to be functional intellectual property and allocated $143.6 million of the transaction price to the licenses and recorded $143.6 million of licenses and royalties revenues in the three-months ended March 31, 2021. The Company also concluded the additional contingent consideration represents variable consideration that is subject to a sales/usage-based threshold and is dependent up on the IP License. The Company is required to apply the royalty recognition constrain guidance in ASC 606-10-55-65 and will recognize revenue at the later of (1) when the underlying sales or usage has occurred and (2) the related performance obligation has been satisfied (or partially satisfied). The Company recorded $8.8 million of license and royalties revenue and a corresponding contract asset under the contingent consideration provisions of the agreements during the three-months ended March 31, 2022. Contract Assets and Liabilities When a contract results i n revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer. Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company. Contract Balances The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers: (In thousands) March 31, 2022 December 31, 2021 Accounts receivable, net $ 37,400 $ 37,074 Accounts receivable - related party, net $ 7,279 $ 5,667 Contract assets $ 3,883 $ 4,227 Contract assets - related party $ 8,816 $ — Contract liabilities $ 1,554 $ 2,530 Contract liabilities, noncurrent (1) $ — $ 111 (1) As of March 31, 2022 and December 31, 2021, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets. Remaining Performance Obligations The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2022. (In thousands) As of March 31, 2022 Remaining 2022 $ 718 2023 143 2024 143 2025 143 2026 and thereafter 143 Total from all customers $ 1,290 In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual property.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Related Party Debt Related party debt was as follows: March 31, 2022 December 31, 2021 In thousands Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Foris convertible note (due July 2022) $ 50,041 $ — $ 36,589 $ 86,630 $ 50,041 $ — $ 57,386 $ 107,427 Related Party Equity There we no related party equity transactions during the three months ended March 31, 2022. Related Party Accounts Receivable, Unbilled Receivables and Accounts Payable Related party accounts receivable, contract assets and accounts payable were as follows: (In thousands) March 31, 2022 December 31, 2021 Accounts receivable - related party $ 7,279 $ 5,667 Accounts payable - related party $ 4,945 $ 5,011

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation The Company’s stock option activity and related information for the three months ended March 31, 2022 was as follows: Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2021 3,087,225 $ 9.91 7.1 $ 2,580 Granted 852,667 $ 3.95 Exercised (34,541) $ 2.83 Forfeited or expired (105,037) $ 6.75 Outstanding - March 31, 2022 3,800,314 $ 8.73 7.6 $ 1,155 Vested or expected to vest after March 31, 2022 3,800,314 $ 8.73 7.6 $ 1,155 Exercisable at March 31, 2022 1,648,914 $ 11.52 5.7 $ 461 Activity related to the Company’s restricted stock units (RSUs) (including performance-based restricted stock units (PSUs)) for the three months ended March 31, 2022 was as follows: Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2021 13,731,320 $ 9.99 2.8 Awarded 4,423,978 $ 3.98 Released (545,114) $ 6.25 Forfeited (304,847) $ 7.41 Outstanding - March 31, 2022 17,305,337 $ 8.62 2.5 Vested or expected to vest after March 31, 2022 17,305,337 $ 8.62 2.5 Stock-based compensation expense during the three months ended March 31, 2022 and 2021 is reflected in the condensed consolidated statements of operations as follows: Three Months Ended March 31, (In thousands) 2022 2021 Cost of products sold $ 78 $ 63 Research and development 1,617 1,062 Sales, general and administrative 9,893 3,156 Total stock-based compensation expense $ 11,588 $ 4,281 As of March 31, 2022, $130.2 million of unrecognized compensation expense related to stock options and RSUs is expected to be recognized over a weighted-average period of 3.3 years.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsNone.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of accounting	The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
Use of Estimates and Judgements	Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed.
Accounting Update Recently Adopted and Accounting Standards or Updates Not Yet Adopted	Accounting Update Recently Adopted In the three months ended March 31, 2022, the Company adopted this accounting update: Convertible Debt, and Derivatives and Hedging . In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 became effective for the Company in the first quarter of 2022. Adoption of this standard on January 1, 2022 in connection with the 2026 Convertible Senior Notes (see Note 4, "Debt"), decreased additional paid-in capital by $368.0 million, increased debt by the same amount and decreased accumulated deficit by $6.0 million for debt discount accretion expense that was recorded prior to adoption. Accounting Standards or Updates Not Yet Adopted Credit Losses . In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. Because the Company met the SEC definition of a smaller reporting company when ASU 2016-13 was issued, this new accounting standard will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures. Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers . This standard will be effective for the Company in the first quarter of 2023 and will be applied prospectively to business combinations occurring on or after the effective date of the standard. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the guidance and the impact on its consolidated financial statements and related disclosures.

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Allowance for Doubtful Accounts	Allowance for Doubtful Accounts (In thousands) Balance at Beginning of Period Provisions Write-offs, Net Balance at End of Period Three months ended March 31, 2022 $ 945 $ 20 $ — $ 965 Three months ended March 31, 2021 $ 137 $ 17 $ — $ 154
Schedule of Inventories	Inventories (In thousands) March 31, 2022 December 31, 2021 Raw materials $ 27,764 $ 25,733 Work-in-process 6,949 6,941 Finished goods 47,583 42,396 Inventories $ 82,296 $ 75,070
Schedule of Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets (In thousands) March 31, 2022 December 31, 2021 Prepayments, advances and deposits $ 34,444 $ 25,140 Non-inventory production supplies 3,762 3,956 Recoverable taxes from Brazilian government entities 1,298 1,188 Other 3,698 3,229 Total prepaid expenses and other current assets $ 43,202 $ 33,513
Schedule of Property, Plant and Equipment, Net	Property, Plant and Equipment, Net (In thousands) March 31, 2022 December 31, 2021 Manufacturing facilities and equipment $ 69,126 $ 51,855 Leasehold improvements 48,483 45,780 Computers and software 9,481 9,174 Furniture and office equipment, vehicles and land 3,789 3,688 Construction in progress 89,656 48,032 220,535 158,529 Less: accumulated depreciation and amortization (95,271) (85,694) Property, plant and equipment, net $ 125,264 $ 72,835
Schedule of Depreciation and Amortization	During the three months ended March 31, 2022 and 2021, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows: Three Months Ended March 31, (In thousands) 2022 2021 Depreciation and amortization expense $ 2,400 $ 2,114
Schedule of Goodwill	The changes in the carrying amount of goodwill were as follows: (In thousands) March 31, 2022 Balance at beginning of year $ 131,259 Acquisitions 7,666 Effect of currency translation adjustment (2,920) Ending balance $ 136,005
Schedule of Finite-Lived Intangible Assets	The following table summarizes the components of intangible assets (in thousands, except estimated useful life): March 31, 2022 December 31, 2021 Amounts in thousands Estimated Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net Trademarks and trade names, and branded products 10 $ 25,704 $ (953) $ 24,751 $ 11,484 $ (496) $ 10,988 Customer relationships 5 - 16 8,638 (474) 8,164 8,197 (267) 7,930 Developed technology and software applications 5 - 12 23,003 (400) 22,603 19,962 (200) 19,762 Patents 17 600 (24) 576 600 (15) 585 Total intangible assets $ 57,945 $ (1,851) $ 56,094 $ 40,243 $ (978) $ 39,265
Schedule of Finite-lived Intangible Assets Amortization Expense	Total future amortization of intangible assets as of March 31, 2022 is as follows (in thousands): Amounts in thousands 2022 (remainder) $ 3,188 2023 5,875 2024 7,027 2025 7,177 2026 6,933 Thereafter 25,894 Total future amortization $ 56,094
Schedule of Lease, Cost	Information related to the Company's right-of-use assets and related lease liabilities were as follows: Three Months Ended March 31, 2022 2021 Cash paid for operating lease liabilities, in thousands $3,045 $1,185 Right-of-use assets obtained in exchange for new operating lease obligations, in thousands $18,759 $— Weighted-average remaining lease term 8.7 2.7 Weighted-average discount rate 19.0% 18.0%
Schedule of Lessee, Lease Liability, Maturity	Maturities of lease liabilities as of March 31, 2022 were as follows: Years ending December 31: (In thousands) Financing Operating Total Leases 2022 (Remaining Nine Months) $ 16 $ 10,038 $ 10,054 2023 22 11,638 11,660 2024 21 9,145 9,166 2025 21 8,964 8,985 2026 16 8,953 8,969 Thereafter — 51,221 51,221 Total lease payments 96 99,959 100,055 Less: amount representing interest (26) (54,780) (54,806) Total lease liability $ 70 $ 45,179 $ 45,249 Current lease liability $ 12 $ 8,120 $ 8,132 Noncurrent lease liability 58 37,059 37,117 Total lease liability $ 70 $ 45,179 $ 45,249
Schedule of Other Assets	Other Assets (In thousands) March 31, 2022 December 31, 2021 Investment in non-trade receivable (1) $ 10,049 $ — Equity-method investments in affiliates 9,654 9,443 Deposits 447 129 Other 3,384 994 Total other assets $ 23,534 $ 10,566 ______________ (1) In March 2022, the Company loaned a privately held company $10 million in exchange for a senior secured convertible promissory note (the Note) which matures in March 2025, unless earlier redeemed or converted into equity of the privately held company. The Note bears interest at 8% per annum and is convertible, at the Company's option, into equity of the privately held company upon maturity of the Note or in the event of an initial public offering, equity financing, or corporate transaction (such as a sale or merger), in each case, at a conversion price that is dependent on a variety of factors. In addition, the Note is redeemable prior to maturity, at the issuer's option, in the event of one or more equity or debt financings, one or more asset sales, or an initial public offering, in each case equal to or greater than $50 million in the aggregate. The Company concluded that the arrangement qualifies for accounting as a loan as required by ASC 310-10. The Company will periodically evaluate the collectibility of the loan, and an allowance for credit losses will be recorded when the Company concludes that all or a portion of the loan balance is no longer collectible.
Schedule of Accrued and Other Current Liabilities	Accrued and Other Current Liabilities (In thousands) March 31, 2022 December 31, 2021 Business acquisitions contingent consideration payable (1) $ 24,872 $ — Accrued interest 12,957 9,572 Payroll and related expenses 11,178 9,151 Liability in connection with acquisition of equity-method investment 9,309 8,735 Beauty Labs deferred consideration payable (2) 5,369 30,000 Asset retirement obligation (3) 4,145 3,336 Professional services 3,057 2,447 Contract termination fees 1,407 1,345 Tax-related liabilities 1,233 988 License fee payable 1,050 1,050 Other 5,977 4,833 Total accrued and other current liabilities $ 80,554 $ 71,457 ______________ (1) Business acquisitions contingent consideration payable is the current portion of total acquisition-related contingent consideration. (2) Approximately $23.7 million of the $30.0 million of Beauty Labs deferred consideration was settled with Amyris common stock in March 2022. (3) The asset retirement obligation represents liabilities incurred but not yet discharged in connection with the Company's 2013 abandonment of a partially constructed facility in Pradópolis, Brazil.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) March 31, 2022 December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities Foris Convertible Note (LSA Amendment) $ — $ — $ 86,630 $ 86,630 $ — $ — $ 107,427 $ 107,427 Freestanding derivative instruments issued in connection with debt and equity instruments — — 5,247 5,247 — — 7,062 7,062 Total liabilities measured and recorded at fair value $ — $ — $ 91,877 $ 91,877 $ — $ — $ 114,489 $ 114,489
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The fair value of contingent consideration is classified as Level 3. The changes in fair value are as follows: (In thousands) March 31, 2022 Beginning balance January 1, 2022 $ 64,762 MenoLabs acquisition 440 Adjustment (79) Change in fair value of contingent consideration — Ending balance March 31, 2022 $ 65,123
Schedule of Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation	The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3): (In thousands) Derivative Liability Balance at December 31, 2021 $ 7,062 Change in fair value of derivative instruments (1,815) Derecognition on settlement or extinguishment — Balance at March 31, 2022 $ 5,247
Schedule of Fair Value Measurement Inputs and Valuation Techniques	Input assumptions for the freestanding instrument are as follows: Range for the Period Input assumptions for liability classified warrants: March 31, 2022 December 31, 2021 Fair value of common stock on issue date $4.36 $5.41 Exercise price of warrants $2.87 $2.87 Expected volatility 106% 107% Risk-free interest rate 2.28% 0.07% – 0.28% Expected term in years 2 2 Dividend yield 0.0 % 0.0 %

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Net carrying amounts of debt are as follows: March 31, 2022 December 31, 2021 (In thousands) Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Convertible notes 2026 convertible senior notes $ 690,000 $ (17,995) $ — $ 672,005 $ 690,000 $ (380,939) $ — $ 309,061 Related party convertible notes Foris convertible note (due July 2022) 50,041 — 36,589 86,630 50,041 — 57,386 107,427 Loans payable and credit facilities Other loans payable (revolving) 1,055 — — 1,055 896 — — 896 Total debt $ 741,096 $ (17,995) $ 36,589 759,690 $ 740,937 $ (380,939) $ 57,386 417,384 Less: current portion (87,686) (108,323) Long-term debt, net of current portion $ 672,004 $ 309,061
Schedule of Long-term Debt Instruments	Future minimum payments under the Company's debt agreements as of March 31, 2022 are as follows: (In thousands) Convertible Notes Related Party Convertible Notes Loans Total 2022 (Remaining Nine Months) $ 10,321 $ 59,578 $ 157 $ 70,056 2023 10,350 — 1,129 11,479 2024 10,350 — — 10,350 2025 10,350 — — 10,350 2026 700,379 — — 700,379 Thereafter — — — — Total future minimum payments 741,750 59,578 1,286 802,614 Less: amount representing interest (51,750) (9,537) (231) (61,518) Present value of minimum debt payments 690,000 50,041 1,055 741,096 Less: current portion of debt principal — (50,041) — (50,041) Noncurrent portion of debt principal $ 690,000 $ — $ 1,055 $ 691,055
Interest Income and Interest Expense Disclosure	Interest expense was as follows: Three Months Ended March 31, (In thousands) 2022 2021 Contractual interest expense in connection with debt $ 3,415 $ 3,553 Debt discount accretion 962 713 Interest expense in connection with debt 4,377 4,266 Financing lease interest expense 3 165 Discount accretion on liability in connection with acquisition of equity-method investment and with partnership liability, and other 883 1,382 Total interest expense $ 5,263 $ 5,813

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Warrants and Rights Activity Summary	The following table summarizes warrants outstanding at March 31, 2022: Transaction Year Issued Expiration Date Number Outstanding as of December 31, 2021 Exercises Expired Exercise Price per Share of Warrants Exercised Number Outstanding as of March 31, 2022 Exercise Price per Share as of March 31, 2022 Blackwell / Silverback warrants 2020 July 10, 2022 1,000,000 — — 1,000,000 $ 3.25 January 2020 warrant exercise right shares 2020 January 31, 2022 431,378 (431,378) — $ 2.87 — $ — May 2019 6.50% Note Exchange warrants 2019 January 31, 2022 960,225 (960,225) — $ 2.87 — $ — May 2017 cash warrants 2017 July 10, 2022 1,492,652 — 1,492,652 $ 2.87 May 2017 dilution warrants 2017 July 10, 2022 56,910 — — 56,910 $ — July 2015 related party debt exchange 2015 July 29, 2025 58,690 — — 58,690 $ 0.15 3,999,855 (1,391,603) — $ 2.87 2,608,252

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the purchase price allocation: (In thousands) Trademarks, trade names and other intellectual property $ 8,705 Customer relationships 512 Goodwill 1,023 Less: noncontrolling interest $ (3,072) Total consideration $ 7,168 The following table summarizes the purchase price allocation: (In thousands) Net tangible assets $ 311 Branded products 5,600 Application (App) 3,600 Goodwill 6,642 Total consideration $ 16,153

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table presents the calculation of basic and diluted loss per share: Three Months Ended March 31, (In thousands, except shares and per share amounts) 2022 2021 Numerator: Net loss attributable to Amyris, Inc. $ (107,305) $ (291,251) Less: loss allocated to participating securities — 2,099 Net loss attributable to Amyris, Inc. common stockholders, basic $ (107,305) $ (289,152) Interest on convertible debt 457 — Gain from change in fair value of debt (12,650) — Gain from change in fair value of derivative instruments (1,815) — Net loss attributable to Amyris, Inc. common stockholders, diluted $ (121,313) $ (289,152) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 312,896,452 267,733,555 Net loss per share, basic $ (0.34) $ (1.08) Weighted-average shares of common stock outstanding 312,896,452 267,733,555 Effect of dilutive convertible debt 10,146,017 — Effect of dilutive common stock warrants 669,213 — Weighted-average shares of common stock equivalents used in computing net loss per share of common stock, diluted 323,711,682 267,733,555 Net loss per share, diluted $ (0.37) $ (1.08)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table presents outstanding shares of potentially dilutive securities: Three Months Ended March 31, 2022 2021 Period-end common stock warrants 2,492,652 13,416,235 Convertible promissory notes (1) 86,683,389 19,540,447 Period-end stock options to purchase common stock 3,800,314 6,205,576 Period-end restricted stock units 17,305,337 6,653,640 Contingently issuable common shares 1,718,475 — Period-end preferred stock — 1,943,661 Total potentially dilutive securities excluded from computation of diluted loss per share 112,000,167 47,759,559 ______________ (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Revenue Recognition and Contr_2

Revenue Recognition and Contract Assets and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended March 31, (In thousands) 2022 2021 Renewable Products Licenses and Royalties Collaborations, Grants and Other Total Renewable Products Licenses and Royalties Collaborations, Grants and Other Total North America $ 32,956 $ 433 $ 1,476 $ 34,865 $ 20,090 $ — $ 250 $ 20,340 Europe 7,289 8,880 3,263 19,432 2,972 143,800 2,346 149,118 Asia 1,488 — 192 1,680 4,405 — 2,284 6,689 South America 1,019 — — 1,019 313 — — 313 Other 713 — — 713 399 — — 399 $ 43,465 $ 9,313 $ 4,931 $ 57,709 $ 28,179 $ 143,800 $ 4,880 $ 176,859 The following table presents revenue by major product and service, as well as by management classification: Three Months Ended March 31, (In thousands) 2022 2021 Renewable Products Licenses and Royalties Grants, Collaborations and Other Total Renewable Products Licenses and Royalties Grants, Collaborations and Other Total Consumer $ 32,642 $ 433 $ 1,476 $ 34,551 $ 15,653 $ — $ — $ 15,653 Technology access 10,823 8,880 3,455 23,158 12,526 143,800 4,880 161,206 $ 43,465 $ 9,313 $ 4,931 $ 57,709 $ 28,179 $ 143,800 $ 4,880 $ 176,859
Revenue in Connection with Significant Revenue Agreement	In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2021 Form 10-K), the Company recognized the following revenue: Three Months Ended March 31, (In thousands) 2022 2021 Renewable Products Licenses and Royalties Collaborations, Grants and Other Total Renewable Products Licenses and Royalties Collaborations, Grants and Other Total DSM - related party $ 4,412 $ 8,816 $ 2,000 $ 15,228 $ 1,662 $ 143,612 $ 2,000 $ 147,274 Sephora 7,633 — — 7,633 4,441 — — 4,441 PureCircle 1,551 — — 1,551 — — — — Subtotal revenue from significant revenue agreements 13,596 8,816 2,000 24,412 6,103 143,612 2,000 151,715 Revenue from all other customers 29,869 497 2,931 33,297 22,076 188 2,880 25,144 Total revenue from all customers $ 43,465 $ 9,313 $ 4,931 $ 57,709 $ 28,179 $ 143,800 $ 4,880 $ 176,859
Contract with Customer, Asset and Liability	The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers: (In thousands) March 31, 2022 December 31, 2021 Accounts receivable, net $ 37,400 $ 37,074 Accounts receivable - related party, net $ 7,279 $ 5,667 Contract assets $ 3,883 $ 4,227 Contract assets - related party $ 8,816 $ — Contract liabilities $ 1,554 $ 2,530 Contract liabilities, noncurrent (1) $ — $ 111 (1) As of March 31, 2022 and December 31, 2021, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction	The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2022. (In thousands) As of March 31, 2022 Remaining 2022 $ 718 2023 143 2024 143 2025 143 2026 and thereafter 143 Total from all customers $ 1,290

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Debt	Related party debt was as follows: March 31, 2022 December 31, 2021 In thousands Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Foris convertible note (due July 2022) $ 50,041 $ — $ 36,589 $ 86,630 $ 50,041 $ — $ 57,386 $ 107,427
Schedule of Related Party Accounts Receivables	Related party accounts receivable, contract assets and accounts payable were as follows: (In thousands) March 31, 2022 December 31, 2021 Accounts receivable - related party $ 7,279 $ 5,667 Accounts payable - related party $ 4,945 $ 5,011

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity	The Company’s stock option activity and related information for the three months ended March 31, 2022 was as follows: Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2021 3,087,225 $ 9.91 7.1 $ 2,580 Granted 852,667 $ 3.95 Exercised (34,541) $ 2.83 Forfeited or expired (105,037) $ 6.75 Outstanding - March 31, 2022 3,800,314 $ 8.73 7.6 $ 1,155 Vested or expected to vest after March 31, 2022 3,800,314 $ 8.73 7.6 $ 1,155 Exercisable at March 31, 2022 1,648,914 $ 11.52 5.7 $ 461
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	Activity related to the Company’s restricted stock units (RSUs) (including performance-based restricted stock units (PSUs)) for the three months ended March 31, 2022 was as follows: Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2021 13,731,320 $ 9.99 2.8 Awarded 4,423,978 $ 3.98 Released (545,114) $ 6.25 Forfeited (304,847) $ 7.41 Outstanding - March 31, 2022 17,305,337 $ 8.62 2.5 Vested or expected to vest after March 31, 2022 17,305,337 $ 8.62 2.5
Share-based Payment Arrangement, Expensed and Capitalized, Amount	Stock-based compensation expense during the three months ended March 31, 2022 and 2021 is reflected in the condensed consolidated statements of operations as follows: Three Months Ended March 31, (In thousands) 2022 2021 Cost of products sold $ 78 $ 63 Research and development 1,617 1,062 Sales, general and administrative 9,893 3,156 Total stock-based compensation expense $ 11,588 $ 4,281

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	$ 245,688	$ (162,314)	$ (315,141)	$ (172,045)
Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	2,656,838	2,337,634	2,106,214	1,957,224
Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	(2,357,661)	$ (2,458,973)	$ (2,377,943)	$ (2,086,692)
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	(361,981)
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	(367,974)
Debt increase (decrease)	368,000
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	$ 5,993

Balance Sheet Details - Allowan

Balance Sheet Details - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 945	$ 137
Contract asset credit loss reserve	20	17
Write-offs, Net	0	0
Balance at End of Period	$ 965	$ 154

Balance Sheet Details - Invento

Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 27,764	$ 25,733
Work-in-process	6,949	6,941
Finished goods	47,583	42,396
Inventories	$ 82,296	$ 75,070

Balance Sheet Details - Additio

Balance Sheet Details - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Right-of-use assets under operating leases, net	$ 58,937		$ 32,428
Operating lease liability	45,179		27,500
Operating lease expense	3,700	$ 1,800
Lease, cost	300	$ 200
Finance lease, right-of-use asset amortization	$ 1,300		$ 6,800
Minimum
Property, Plant and Equipment [Line Items]
Operating lease remaining lease term (years)	1 year
Operating lease renewal term (years)	1 year
Maximum
Property, Plant and Equipment [Line Items]
Operating lease remaining lease term (years)	18 years
Operating lease renewal term (years)	5 years

Balance Sheet Details - Prepaid

Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepayments, advances and deposits	$ 34,444	$ 25,140
Non-inventory production supplies	3,762	3,956
Recoverable taxes from Brazilian government entities	1,298	1,188
Other	3,698	3,229
Total prepaid expenses and other current assets	$ 43,202	$ 33,513

Balance Sheet Details - Propert

Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 220,535	$ 158,529
Less: accumulated depreciation and amortization	(95,271)	(85,694)
Property, plant and equipment, net	125,264	72,835
Manufacturing Facility And Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	69,126	51,855
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	48,483	45,780
Computers and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	9,481	9,174
Furniture and office equipment, vehicles and land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,789	3,688
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 89,656	$ 48,032

Balance Sheet Details - Depreci

Balance Sheet Details - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation and amortization expense	$ 2,400	$ 2,114

Balance Sheet Details - Goodwil

Balance Sheet Details - Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill [Roll Forward]
Balance at beginning of year	$ 131,259
Acquisitions	7,666	$ 0
Effect of currency translation adjustment	(2,920)
Ending balance	$ 136,005

Balance Sheet Details - Intangi

Balance Sheet Details - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Acquisition of intangible assets in connection with business combinations	$ 18,400
Gross	57,945		$ 40,243
Accumulated Amortization	(1,851)		(978)
Net	56,094		39,265
Amortization of intangible assets	892	$ 0
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022 (remainder)	3,188
2023	5,875
2024	7,027
2025	7,177
2026	6,933
Thereafter	25,894
Total future amortization	$ 56,094		39,265
Trademarks and trade names, and branded products
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	10 years
Gross	$ 25,704		11,484
Accumulated Amortization	(953)		(496)
Net	24,751		10,988
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total future amortization	24,751		10,988
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross	8,638		8,197
Accumulated Amortization	(474)		(267)
Net	8,164		7,930
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total future amortization	$ 8,164		7,930
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	5 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	16 years
Developed technology and software applications
Finite-Lived Intangible Assets [Line Items]
Gross	$ 23,003		19,962
Accumulated Amortization	(400)		(200)
Net	22,603		19,762
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total future amortization	$ 22,603		19,762
Developed technology and software applications | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	5 years
Developed technology and software applications | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	12 years
Patents
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	17 years
Gross	$ 600		600
Accumulated Amortization	(24)		(15)
Net	576		585
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total future amortization	$ 576		$ 585

Balance Sheet Details - Right-o

Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash paid for operating lease liabilities, in thousands	$ 3,045	$ 1,185
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands	$ 18,759	$ 0
Weighted-average remaining lease term	8 years 8 months 12 days	2 years 8 months 12 days
Weighted-average discount rate	19.00%	18.00%

Balance Sheet Details - Maturit

Balance Sheet Details - Maturities of Financing and Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Financing Leases
2022 (Remaining Nine Months)	$ 16
2023	22
2024	21
2025	21
2026	16
Thereafter	0
Total lease payments	96
Less: amount representing interest	(26)
Total lease liability	70
Current lease liability	12	$ 140
Noncurrent lease liability	58	61
Total lease liability	70
Operating Leases
2022 (Remaining Nine Months)	10,038
2023	11,638
2024	9,145
2025	8,964
2026	8,953
Thereafter	51,221
Total lease payments	99,959
Less: amount representing interest	(54,780)
Total lease liability	45,179	27,500
Current lease liability	8,120	7,689
Noncurrent lease liability	37,059	19,829
Total lease liability	45,179	$ 27,500
2022 (Remaining Nine Months)	10,054
2023	11,660
2024	9,166
2025	8,985
2026	8,969
Thereafter	51,221
Total lease payments	100,055
Less: amount representing interest	(54,806)
Total lease liability	45,249
Current lease liability	8,132
Noncurrent lease liability	37,117
Total lease liability	$ 45,249

Balance Sheet Details - Other A

Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Investment in non-trade receivable	$ 10,049	$ 0
Equity-method investments in affiliates	9,654	9,443
Deposits	447	129
Other	3,384	994
Total other assets	23,534	$ 10,566
2025 Promissory Note | Convertible notes
Debt Instrument [Line Items]
Investment in non-trade receivable	$ 10,000
Debt instrument, interest rate, stated percentage	8.00%
Contingent redemption threshold	$ 50,000

Balance Sheet Details - Accrued

Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Accrued interest	$ 12,957	$ 9,572
Payroll and related expenses	11,178	9,151
Asset retirement obligation	4,145	3,336
Professional services	3,057	2,447
Contract termination fees	1,407	1,345
Tax-related liabilities	1,233	988
License fee payable	1,050	1,050
Other	5,977	4,833
Total accrued and other current liabilities	80,554	71,457
Total Acquisitions
Business Acquisition [Line Items]
Business acquisition, contingent consideration	24,872	0
Equity Method Investment Acquisitions
Business Acquisition [Line Items]
Business acquisition, contingent consideration	9,309	8,735
Beauty Labs
Business Acquisition [Line Items]
Business acquisition, contingent consideration	5,369	$ 30,000
Contingent consideration, liabilities settled with equity	$ 23,700

Fair Value Measurement - Fair V

Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	$ 5,247	$ 7,062
Total liabilities measured and recorded at fair value	91,877	114,489
Foris Convertible Note (LSA Amendment)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	86,630	107,427
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	0	0
Total liabilities measured and recorded at fair value	0	0
Level 1 | Foris Convertible Note (LSA Amendment)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	0	0
Total liabilities measured and recorded at fair value	0	0
Level 2 | Foris Convertible Note (LSA Amendment)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Freestanding derivative instruments issued in connection with debt and equity instruments	5,247	7,062
Total liabilities measured and recorded at fair value	91,877	114,489
Level 3 | Foris Convertible Note (LSA Amendment)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	$ 86,630	$ 107,427

Fair Value Measurement - Fair_2

Fair Value Measurement - Fair Value of Debt — Foris Convertible Note (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / shares	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Principal	$ 741,096		$ 740,937
Long term debt, fair value	759,690		417,384
Gain (loss) from change in fair value of debt	20,796	$ (326,785)
Foris Convertible Note (LSA Amendment) | Related party convertible notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Principal	50,041		50,041
Long term debt, fair value	86,630		$ 107,427
Gain (loss) from change in fair value of debt	$ 20,800
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares	$ 3
Foris Convertible Note (LSA Amendment) | Related party convertible notes | Stock Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares	4.36
Foris Convertible Note (LSA Amendment) | Related party convertible notes | Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.21
Foris Convertible Note (LSA Amendment) | Related party convertible notes | Risk-free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.0052
Foris Convertible Note (LSA Amendment) | Related party convertible notes | Stock Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.45
Foris Convertible Note (LSA Amendment) | Related party convertible notes | Probability of Change in Control
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.05

Fair Value Measurement - Reconc

Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Debt-related Derivative Liability - Level 3 $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	$ 7,062
Change in fair value of derivative instruments	(1,815)
Derecognition on settlement or extinguishment	0
Fair value, ending balance	$ 5,247

Fair Value Measurement - Market

Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details)	Mar. 31, 2022$ / sharesyear	Dec. 31, 2021year$ / shares
Fair value of common stock on issue date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	4.36	5.41
Exercise price of warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	2.87	2.87
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	1.06	1.07
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.0228
Expected term in years
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input | year	2	2
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0	0
Minimum | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input		0.0007
Maximum | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input		0.0028

Fair Value Measurement - Acquis

Fair Value Measurement - Acquisition Related Contingent Consideration Narrative (Details) - MenoLabs LLC	Mar. 31, 2022$ / shares
Revenue Risk Adjustment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent liability, measurement input	0.062
Annual Revenue Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent liability, measurement input	0.35

Fair Value Measurement - Acqu_2

Fair Value Measurement - Acquisition Related Contingent Consideration Consideration Roll forward (Details) - Contingent Consideration, Liability $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	$ 64,762
Adjustment	(79)
Change in fair value of contingent consideration	0
Fair value, ending balance	65,123
MenoLabs LLC
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition liability	$ 440

Fair Value Measurement - Financ

Fair Value Measurement - Financial Assets and Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Combined debt amount	$ 673.1	$ 310
Debt instrument fair value disclosure	$ 249.3	$ 328

Debt - Debt Components (Details

Debt - Debt Components (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal	$ 741,096	$ 740,937
Unaccreted Debt Discount	(17,995)	(380,939)
Change in Fair Value	36,589	57,386
Net	759,690	417,384
Less: current portion	(87,686)	(108,323)
Long-term debt, net of current portion	672,004	309,061
Convertible notes | 2026 convertible senior notes
Debt Instrument [Line Items]
Principal	690,000	690,000
Unaccreted Debt Discount	(17,995)	(380,939)
Change in Fair Value	0	0
Net	672,005	309,061
Related party convertible notes | Foris convertible note (due July 2022)
Debt Instrument [Line Items]
Principal	50,041	50,041
Unaccreted Debt Discount	0	0
Change in Fair Value	36,589	57,386
Net	86,630	107,427
Loans payable and credit facilities | Other loans payable (revolving)
Debt Instrument [Line Items]
Principal	1,055	896
Unaccreted Debt Discount	0	0
Change in Fair Value	0	0
Net	$ 1,055	$ 896

Debt - Adoption of ASU (Details

Debt - Adoption of ASU (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	$ 245,688	$ (162,314)	$ (315,141)	$ (172,045)
Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	2,656,838	2,337,634	2,106,214	1,957,224
Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	(2,357,661)	$ (2,458,973)	$ (2,377,943)	$ (2,086,692)
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	(361,981)
Cumulative Effect, Period of Adoption, Adjustment | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	(367,974)
Debt increase (decrease)	368,000
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders equity (deficit)	$ 5,993

Debt - Future Minimum Payments

Debt - Future Minimum Payments (Details) $ in Thousands	Mar. 31, 2022USD ($)
Debt Instrument [Line Items]
2022 (Remaining Nine Months)	$ 70,056
2023	11,479
2024	10,350
2025	10,350
2026	700,379
Thereafter	0
Total future minimum payments	802,614
Less: amount representing interest	(61,518)
Present value of minimum debt payments	741,096
Less: current portion of debt principal	(50,041)
Noncurrent portion of debt principal	691,055
Convertible notes
Debt Instrument [Line Items]
2022 (Remaining Nine Months)	10,321
2023	10,350
2024	10,350
2025	10,350
2026	700,379
Thereafter	0
Total future minimum payments	741,750
Less: amount representing interest	(51,750)
Present value of minimum debt payments	690,000
Less: current portion of debt principal	0
Noncurrent portion of debt principal	690,000
Related Party Convertible Notes
Debt Instrument [Line Items]
2022 (Remaining Nine Months)	59,578
2023	0
2024	0
2025	0
2026	0
Thereafter	0
Total future minimum payments	59,578
Less: amount representing interest	(9,537)
Present value of minimum debt payments	50,041
Less: current portion of debt principal	(50,041)
Noncurrent portion of debt principal	0
Loans payable and credit facilities
Debt Instrument [Line Items]
2022 (Remaining Nine Months)	157
2023	1,129
2024	0
2025	0
2026	0
Thereafter	0
Total future minimum payments	1,286
Less: amount representing interest	(231)
Present value of minimum debt payments	1,055
Less: current portion of debt principal	0
Noncurrent portion of debt principal	$ 1,055

Debt - Interest Expense (Detail

Debt - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Disclosure [Abstract]
Contractual interest expense in connection with debt	$ 3,415	$ 3,553
Debt discount accretion	962	713
Interest expense in connection with debt	4,377	4,266
Financing lease interest expense	3	165
Discount accretion on liability in connection with acquisition of equity-method investment and with partnership liability, and other	883	1,382
Total interest expense	$ 5,263	$ 5,813

Mezzanine Equity - Gates Founda

Mezzanine Equity - Gates Foundation (Details) - Gates Foundation Purchase Agreement $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)$ / shares
Subsidiary, Sale of Stock [Line Items]
Stock price (in dollars per share) | $ / shares	$ 17.10
Compound annual return (percentage)	10.00%
Research and development obligation, remaining amount | $	$ 0.2

Mezzanine Equity - Ingredion Co

Mezzanine Equity - Ingredion Contingently Redeemable Noncontrolling Interest In Subsidiary (Details) - RealSweet LLC - USD ($) $ in Millions	Jun. 01, 2021	Dec. 31, 2022	Mar. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Ownership percentage by noncontrolling owners	31.00%
Ownership percentage	100.00%
Increase from sale of parent equity interest	$ 28.5
Proceeds from issuance of contingently redeemable noncontrolling interest in subsidiary	$ 10
Noncontrolling interest, ownership percentage threshold	8.40%
Issuance of contingently redeemable noncontrolling interest	$ 28.5
Amount funded			$ 68
Purchase commitment			$ 38
Forecast
Subsidiary, Sale of Stock [Line Items]
Purchase commitment		$ 115
Amyris, Inc.
Subsidiary, Sale of Stock [Line Items]
Payments to noncontrolling interests	4
Intangible assets transferred	$ 14.5

Mezzanine Equity - EcoFabulous

Mezzanine Equity - EcoFabulous Contingently Redeemable Noncontrolling Interest in Subsidiary (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jan. 26, 2022	May 07, 2021
Subsidiary, Sale of Stock [Line Items]
Loss (income) attributable to noncontrolling interest	$ (2,928,000)	$ 1,200,000
EcoFab LLC
Subsidiary, Sale of Stock [Line Items]
Percentage of voting interests acquired			70.00%	70.00%
Business acquisition, contingent revenue threshold			$ 100,000,000
Issuance of contingently redeemable noncontrolling interest	2,900,000
Noncontrolling interest recorded in connection with business combinations	$ 3,100,000		$ 3,072,000
EcoFab LLC | No Planet B Investments, LLC
Subsidiary, Sale of Stock [Line Items]
Percentage of voting interests acquired	30.00%		30.00%
Business acquisition, contingent percentage of voting interests to be acquired			30.00%
Loss (income) attributable to noncontrolling interest	$ 200,000

Stockholders' Deficit - Warrant

Stockholders' Deficit - Warrants and Rights Activity Summary (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Class of Warrant or Right [Line Items]
Number outstanding, beginning balance (in shares)	3,999,855
Exercises (in shares)	(1,391,603)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Number outstanding, ending balance (in shares)	2,608,252
Blackwell / Silverback warrants
Class of Warrant or Right [Line Items]
Number outstanding, beginning balance (in shares)	1,000,000
Exercises (in shares)	0
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares
Number outstanding, ending balance (in shares)	1,000,000
Exercise price per share (in dollars per share) | $ / shares	$ 3.25
January 2020 warrant exercise right shares
Class of Warrant or Right [Line Items]
Number outstanding, beginning balance (in shares)	431,378
Exercises (in shares)	(431,378)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Number outstanding, ending balance (in shares)	0
Exercise price per share (in dollars per share) | $ / shares	$ 0
May 2019 6.50% Note Exchange warrants
Class of Warrant or Right [Line Items]
Number outstanding, beginning balance (in shares)	960,225
Exercises (in shares)	(960,225)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Number outstanding, ending balance (in shares)	0
Exercise price per share (in dollars per share) | $ / shares	$ 0
May 2017 cash warrants
Class of Warrant or Right [Line Items]
Number outstanding, beginning balance (in shares)	1,492,652
Exercises (in shares)
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares
Number outstanding, ending balance (in shares)	1,492,652
Exercise price per share (in dollars per share) | $ / shares	$ 2.87
May 2017 dilution warrants
Class of Warrant or Right [Line Items]
Number outstanding, beginning balance (in shares)	56,910
Exercises (in shares)	0
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares
Number outstanding, ending balance (in shares)	56,910
Exercise price per share (in dollars per share) | $ / shares	$ 0
July 2015 related party debt exchange
Class of Warrant or Right [Line Items]
Number outstanding, beginning balance (in shares)	58,690
Exercises (in shares)	0
Expired (in shares)	0
Exercise price per share of warrants exercised (in dollars per share) | $ / shares
Number outstanding, ending balance (in shares)	58,690
Exercise price per share (in dollars per share) | $ / shares	$ 0.15

Stockholders' Deficit - Warra_2

Stockholders' Deficit - Warrant Activity (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Equity [Abstract]
Exercises (in shares) | shares	1,391,603
Exercise price per share of warrants exercised (in dollars per share) | $ / shares	$ 2.87
Proceeds from warrant exercise, including portion attributable to related party | $	$ 4

Acquisitions - EcoFab LLC, Narr

Acquisitions - EcoFab LLC, Narrative (Details) - EcoFab LLC - USD ($) $ in Thousands	Jan. 26, 2022	Mar. 31, 2022	May 07, 2021
Business Acquisition, Contingent Consideration [Line Items]
Percentage of voting interests acquired	70.00%		70.00%
Payments to acquire business	$ 1,700
Business acquisition, equity interest issued or issuable, shares (in shares)	1,292,776
Business acquisition, equity interest issued or issuable	$ 5,500
Noncontrolling interest recorded in connection with business combinations	$ 3,072	$ 3,100
No Planet B Investments, LLC
Business Acquisition, Contingent Consideration [Line Items]
Percentage of voting interests acquired	30.00%	30.00%

Acquisitions - EcoLab LLC, Asse

Acquisitions - EcoLab LLC, Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 26, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Goodwill	$ 136,005		$ 131,259
EcoFab LLC
Business Acquisition, Contingent Consideration [Line Items]
Goodwill		$ 1,023
Less: noncontrolling interest	$ (3,100)	(3,072)
Total consideration		7,168
EcoFab LLC | Trademarks, trade names and other intellectual property
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		8,705
EcoFab LLC | Customer relationships
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		$ 512

Acquisitions - MenoLabs LLC, Na

Acquisitions - MenoLabs LLC, Narrative (Details) - USD ($) $ in Thousands	Mar. 09, 2022	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Principal		$ 741,096	$ 740,937
MenoLabs LLC
Business Acquisition, Contingent Consideration [Line Items]
Consideration transferred	$ 16,200
Payments to acquire business	11,300
Business combination, debt incurred	$ 500
Business acquisition, equity interest issued or issuable, shares (in shares)	852,234
Business acquisition, equity interest issued or issuable	$ 3,900
Business combination, consideration transferred, other	400
Business combination, contingent consideration, liability	400
MenoLabs LLC | Earnout Payment One
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration, earnout payments	10,000
MenoLabs LLC | Earnout Payment Two
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration, earnout payments	10,000
Bridge Loan | MenoLabs LLC
Business Acquisition, Contingent Consideration [Line Items]
Principal	$ 500

Acquisitions - MenoLabs LLC, As

Acquisitions - MenoLabs LLC, Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 09, 2022	Dec. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Goodwill	$ 136,005		$ 131,259
MenoLabs LLC
Business Acquisition, Contingent Consideration [Line Items]
Net tangible assets		$ 311
Goodwill		6,642
Total consideration		16,153
MenoLabs LLC | Branded products
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		5,600
MenoLabs LLC | Application (App)
Business Acquisition, Contingent Consideration [Line Items]
Intangible assets, other than goodwill		$ 3,600

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss attributable to Amyris, Inc.	$ (107,305)	$ (291,251)
Less: loss allocated to participating securities	0	2,099
Net loss attributable to Amyris, Inc. common stockholders, basic	(107,305)	(289,152)
Interest on convertible debt	457	0
Gain from change in fair value of debt	(12,650)	0
Gain (loss) from change in fair value of derivative instruments	(1,815)	0
Net loss attributable to Amyris, Inc. common stockholders, diluted	$ (121,313)	$ (289,152)
Denominator:
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)	312,896,452	267,733,555
Net loss per share, basic (in dollars per share)	$ (0.34)	$ (1.08)
Effect of dilutive convertible debt (in shares)	10,146,017	0
Effect of dilutive common stock warrants (in shares)	669,213	0
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)	323,711,682	267,733,555
Net loss per share, diluted (in dollars per share)	$ (0.37)	$ (1.08)

Net Loss per Share Attributab_4

Net Loss per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	112,000,167	47,759,559
Period-end common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	2,492,652	13,416,235
Convertible promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	86,683,389	19,540,447
Period-end stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	3,800,314	6,205,576
Period-end restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	17,305,337	6,653,640
Contingently issuable common shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	1,718,475	0
Period-end preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares)	0	1,943,661

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended
	Oct. 31, 2021	Mar. 31, 2022	Dec. 31, 2021
Renfield Manufacturing, LLC
Product Liability Contingency [Line Items]
Liabilities recorded for agreements		$ 0	$ 0
Guarantor Arrangements, Agreement Term	10 years
Letter of Credit
Product Liability Contingency [Line Items]
Long-term, line of credit	$ 500,000

Revenue Recognition and Contr_3

Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 57,709	$ 176,859
Consumer
Disaggregation of Revenue [Line Items]
Revenue	34,551	15,653
Technology access
Disaggregation of Revenue [Line Items]
Revenue	23,158	161,206
North America
Disaggregation of Revenue [Line Items]
Revenue	34,865	20,340
Europe
Disaggregation of Revenue [Line Items]
Revenue	19,432	149,118
Asia
Disaggregation of Revenue [Line Items]
Revenue	1,680	6,689
South America
Disaggregation of Revenue [Line Items]
Revenue	1,019	313
Other
Disaggregation of Revenue [Line Items]
Revenue	713	399
Renewable Products
Disaggregation of Revenue [Line Items]
Revenue	43,465	28,179
Renewable Products | Consumer
Disaggregation of Revenue [Line Items]
Revenue	32,642	15,653
Renewable Products | Technology access
Disaggregation of Revenue [Line Items]
Revenue	10,823	12,526
Renewable Products | North America
Disaggregation of Revenue [Line Items]
Revenue	32,956	20,090
Renewable Products | Europe
Disaggregation of Revenue [Line Items]
Revenue	7,289	2,972
Renewable Products | Asia
Disaggregation of Revenue [Line Items]
Revenue	1,488	4,405
Renewable Products | South America
Disaggregation of Revenue [Line Items]
Revenue	1,019	313
Renewable Products | Other
Disaggregation of Revenue [Line Items]
Revenue	713	399
Licenses and Royalties
Disaggregation of Revenue [Line Items]
Revenue	9,313	143,800
Licenses and Royalties | Consumer
Disaggregation of Revenue [Line Items]
Revenue	433	0
Licenses and Royalties | Technology access
Disaggregation of Revenue [Line Items]
Revenue	8,880	143,800
Licenses and Royalties | North America
Disaggregation of Revenue [Line Items]
Revenue	433	0
Licenses and Royalties | Europe
Disaggregation of Revenue [Line Items]
Revenue	8,880	143,800
Licenses and Royalties | Asia
Disaggregation of Revenue [Line Items]
Revenue	0	0
Licenses and Royalties | South America
Disaggregation of Revenue [Line Items]
Revenue	0	0
Licenses and Royalties | Other
Disaggregation of Revenue [Line Items]
Revenue	0	0
Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	4,931	4,880
Collaborations, Grants and Other | Consumer
Disaggregation of Revenue [Line Items]
Revenue	1,476	0
Collaborations, Grants and Other | Technology access
Disaggregation of Revenue [Line Items]
Revenue	3,455	4,880
Collaborations, Grants and Other | North America
Disaggregation of Revenue [Line Items]
Revenue	1,476	250
Collaborations, Grants and Other | Europe
Disaggregation of Revenue [Line Items]
Revenue	3,263	2,346
Collaborations, Grants and Other | Asia
Disaggregation of Revenue [Line Items]
Revenue	192	2,284
Collaborations, Grants and Other | South America
Disaggregation of Revenue [Line Items]
Revenue	0	0
Collaborations, Grants and Other | Other
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ 0

Revenue Recognition and Contr_4

Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 57,709	$ 176,859
Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	24,412	151,715
Renewable Products
Disaggregation of Revenue [Line Items]
Revenue	43,465	28,179
Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	13,596	6,103
Licenses and Royalties
Disaggregation of Revenue [Line Items]
Revenue	9,313	143,800
Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	8,816	143,612
Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	4,931	4,880
Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	2,000	2,000
DSM - related party | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	15,228	147,274
DSM - related party | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	4,412	1,662
DSM - related party | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	8,816	143,612
DSM - related party | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	2,000	2,000
Sephora | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	7,633	4,441
Sephora | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	7,633	4,441
Sephora | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	0
Sephora | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	0
PureCircle | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	1,551	0
PureCircle | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	1,551	0
PureCircle | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	0
PureCircle | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	0	0
Revenue from all other customers | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	33,297	25,144
Revenue from all other customers | Renewable Products | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	29,869	22,076
Revenue from all other customers | Licenses and Royalties | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	497	188
Revenue from all other customers | Collaborations, Grants and Other | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	$ 2,931	$ 2,880

Revenue Recognition and Contr_5

Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 57,709	$ 176,859
Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	4,931	4,880
Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	24,412	151,715
Significant Revenue Agreement | Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	2,000	2,000
DSM - related party | DSM Ingredients Collaboration | Research and Development
Disaggregation of Revenue [Line Items]
Quarterly payments	2,000
DSM - related party | Significant Revenue Agreement
Disaggregation of Revenue [Line Items]
Revenue	15,228	147,274
DSM - related party | Significant Revenue Agreement | Collaborations, Grants and Other
Disaggregation of Revenue [Line Items]
Revenue	$ 2,000	$ 2,000

Revenue Recognition and Contr_6

Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Accounts receivable, net	$ 37,400	$ 37,074
Accounts receivable - related party, net	7,279	5,667
Contract assets	3,883	4,227
Contract assets - related party	8,816	0
Contract liabilities	1,554	2,530
Contract liabilities, noncurrent	$ 0	$ 111

Revenue Recognition and Contr_7

Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) $ in Thousands	Mar. 31, 2022USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, Amount	$ 1,290
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	9 months
Revenue, remaining performance obligation, Amount	$ 718
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, remaining performance obligation, Amount	$ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, remaining performance obligation, Amount	$ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, remaining performance obligation, Amount	$ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, remaining performance obligation, Amount	$ 143

Related Party Transactions - Re

Related Party Transactions - Related Party Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Principal	$ 741,096	$ 740,937
Change in Fair Value	36,589	57,386
Net	759,690	417,384
Foris Ventures LLC | Related Party Debt | Foris convertible note (due July 2022)
Related Party Transaction [Line Items]
Principal	50,041	50,041
Unaccreted Debt Discount	0	0
Change in Fair Value	36,589	57,386
Net	$ 86,630	$ 107,427

Related Party Transactions - _2

Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Accounts payable - related party	$ 86,630	$ 107,427
Accounts receivable - related party
Related Party Transaction [Line Items]
Accounts receivable - related party	7,279	5,667
Accounts payable - related party
Related Party Transaction [Line Items]
Accounts payable - related party	$ 4,945	$ 5,011

Stock-based Compensation - Shar

Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Quantity of Stock Options
Outstanding, beginning balance (in shares)	3,087,225
Granted (in shares)	852,667
Exercised (in shares)	(34,541)
Forfeited or expired (in shares)	(105,037)
Outstanding, ending balance (in shares)	3,800,314	3,087,225
Vested or expected to vest (in shares)	3,800,314
Exercisable (in shares)	1,648,914
Weighted- average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 9.91
Granted (in dollars per share)	3.95
Exercised (in dollars per share)	2.83
Forfeited or expired (in dollars per share)	6.75
Outstanding, ending balance (in dollars per share)	8.73	$ 9.91
Vested or expected to vest (in dollars per share)	8.73
Exercisable (in dollars per share)	$ 11.52
Weighted-average Remaining Contractual Life, in Years
Outstanding (years)	7 years 7 months 6 days	7 years 1 month 6 days
Vested or expected to vest (years)	7 years 7 months 6 days
Exercisable (years)	5 years 8 months 12 days
Aggregate Intrinsic Value, in Thousands
Outstanding (years)	$ 1,155	$ 2,580
Vested or expected to vest	1,155
Exercisable	$ 461

Stock-based Compensation - Temp

Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Quantity of Restricted Stock Units
Outstanding , beginning balance (in shares)	13,731,320
Awarded (in shares)	4,423,978
Released (in shares)	(545,114)
Forfeited (in shares)	(304,847)
Outstanding, ending balance (in shares)	17,305,337	13,731,320
Vested or expected to vest (in shares)	17,305,337
Weighted-average Grant-date Fair Value
Outstanding, beginning balance (in dollars per share)	$ 9.99
Awarded (in dollars per share)	3.98
Released (in dollars per share)	6.25
Forfeited (in dollars per share)	7.41
Outstanding, ending balance (in dollars per share)	8.62	$ 9.99
Vested or expected to vest (in dollars per share)	$ 8.62
Weighted-average Remaining Contractual Life, in Years
Outstanding (years)	2 years 6 months	2 years 9 months 18 days
Vested or expected to vest (years)	2 years 6 months

Stock-based Compensation - Empl

Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 11,588	$ 4,281
Cost of products sold
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	78	63
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	1,617	1,062
Sales, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 9,893	$ 3,156

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Share-based Payment Arrangement [Abstract]
Compensation expense related to stock options and RSUs	$ 130.2
Weighted-average period	3 years 3 months 18 days